-
Diagnostics World News | At Scope X, Novo Nordisk gave a presentation on how high-impact opportunities for leveraging AI across the pharmaceutical R&D cycle are too numerous to count but won’t “automagically” solve any of the longstanding problems in ushering molecules to market. AI requires human attention to match tools to tasks for ensuring the accuracy of model predictions, and the pitfalls are dangerously easy to miss,
May 27, 2026
-
Diagnostics World News | Isomorphic Labs plans to continue development and deployment of its AI drug design engine; NVision expands POLARIS platform into quantum computation; Kanvas Biosciences advances commercial partnerships that leverage the company’s spatial imaging and manufacturing platform; and more.
May 26, 2026
-
Diagnostics World News | Researchers at the Oregon Health and Science University have established a rapid blood test to differentiate pancreatic cancer from other pancreatic conditions. The method involves the analysis of tumor-secreted nanoparticles on a specialized chip and actually outperforms the gold-standard needle-based biopsy diagnosis.
May 21, 2026
-
Diagnostics World News | For patients seeing a cardiologist, their diagnosis and next steps rest on data gathered at a single point in time: the day of their appointment. One blood pressure reading. One imaging scan. One day’s data to define the health of a continuously changing system. The Duke Center for Computational and Digital Health Innovation developed a platform that may be a better way.
May 19, 2026
-
Diagnostics World News | During pregnancy, the cells of a fetus make their way into the tissues of mom where they can persist for decades, much like what happens when someone gets an organ transplant but to a far tinier extent. That the maternal-fetal exchange results in chimerism—more specifically, “microchimerism”—is a relatively little-known yet fascinating and profoundly common biological phenomenon.
May 14, 2026
-
Diagnostics World News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics.
May 13, 2026
-
Diagnostics World News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics.
May 13, 2026
-
Diagnostics World News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence (AI) and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget.
May 12, 2026
-
Diagnostics World News | There’s a seductive promise baked into the rise of large language models: that a single, powerful AI trained on the breadth of human knowledge can do virtually anything. Need to draft a contract? Summarize a research paper? Predict whether a drug molecule will cross the blood-brain barrier? Just ask GPT. But ask the executives building AI tools inside two highly specialized fields — radiology and early-stage drug discovery — and they’ll tell you that promise breaks down the moment you need answers that actually matter.
May 7, 2026
-
Diagnostics World News | There’s a seductive promise baked into the rise of large language models: that a single, powerful AI trained on the breadth of human knowledge can do virtually anything. Need to draft a contract? Summarize a research paper? Predict whether a drug molecule will cross the blood-brain barrier? Just ask GPT. But ask the executives building AI tools inside two highly specialized fields — radiology and early-stage drug discovery — and they’ll tell you that promise breaks down the moment you need answers that actually matter.
May 7, 2026
-
Diagnostics World | The diagnosis and management of hypertension is in a troublingly bleak state, despite myriad treatments and regular blood pressure checks in primary care settings intended to catch the condition early. The conundrum is rooted in a trio of problems that co-exist like “gears with broken teeth that don’t mesh together very well."
May 5, 2026
-
Diagnostics World | Alloy speeds up growth to deepen its core discovery service in antibodies, genetic medicines, and cell therapies; RyboDyn accelerates transition from foundational discovery into scaled platform execution and progresses early-stage programs into IND-enabling studies; and more.
Apr 30, 2026